高龄女性极体活检PGT-A的经济学分析
该研究基于ESTEEM随机临床试验,用决策树模型比较36-40岁不孕女性单周期IVF/ICSI联合或不联合极体活检PGT-A(aCGH)的成本效果。PGT-A使每活产成本在高成本情景增加约15%、低成本情景增加约285%,每避免一次流产的增量成本为34,427至51,146美元(基准假设),概率敏感性分析显示PGT-A具成本效果的概率仅0.0%-1.9%。
要点
- PGT-A使每活产成本在高成本情景增约15%,低成本情景增约285%。
- 阈值分析:需妊娠率绝对提高6%至>39%或PGT-A便宜2,969至4,888美元才具成本效果。
- 基准假设下每避免一次流产的增量成本为34,427至51,146美元。
核心结论
- 避免不必要胚胎移植和流产虽重要,但患者与医生需知晓极体aCGH-PGT-A的高成本 implications。
研究设计与样本
- 决策树模型,基于ESTEEM随机临床试验,比较36-40岁不孕女性单周期IVF/ICSI联合或不联合极体活检PGT-A。
主要发现
- PGT-A使每活产成本在高成本情景增加约15%,低成本情景增加约285%。
- 阈值分析显示PGT-A需妊娠率绝对提高6%至>39%或便宜2,969美元(高成本)至4,888美元(低成本)才具成本效果。
- 基准假设下每避免一次流产的增量成本为34,427美元(高成本情景)至51,146美元(低成本情景)。
- 概率敏感性分析显示PGT-A具成本效果的概率为1.9%(高成本情景)至0.0%(低成本情景)。
临床怎么用
- 在高龄不孕女性中应用极体活检PGT-A前,应充分告知其显著增加每活产成本且避免流产需高额花费。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: What are the cost per live birth and the incremental cost of preventing a miscarriage with preimplantation genetic testing for aneuploidy (PGT-A) by polar body biopsy and array-based comprehensive genome hybridisation (aCGH) versus regular IVF/ICSI without PGT-A for infertility treatment in women 36-40 years of age? DESIGN: Decision tree model. POPULATION: A randomised clinical trial on PGT-A (ESTEEM study). METHODS: Two treatment strategies were compared: one cycle of IVF/ICSI with or without PGT-A. Costs and effects were analysed with this model for four different cost scenarios: high-, higher medium, lower medium and low-cost. Base case, sensitivity, threshold, and probabilistic sensitivity analyses were used to examine the cost-effectiveness implications of PGT-A. RESULTS: PGT-A increased the cost per live birth by approximately 15% in the high-cost scenario to approximately 285% in the low-cost scenario. Threshold analysis revealed that PGT-A would need to be associated with an absolute increase in pregnancy rate by 6% to >39% or, alternatively, would need to be US$2,969 (high-cost scenario) to US$4,888 (low-cost scenario) cheaper. The incremental cost to prevent one miscarriage by PGT-A using the base case assumptions was calculated to be US$34,427 (high-cost scenario) to US$51,146 (low-cost scenario). A probabilistic sensitivity analysis showed cost-effectiveness for PGT-A from 1.9% (high-cost scenario) to 0.0% (low-cost scenario) of calculated samples. CONCLUSIONS: While avoiding unnecessary embryo transfers and miscarriages are important goals, patients and doctors need to be aware of the high-cost implications of applying PGT-A using aCGH on polar bodies. TWEETABLE ABSTRACT: PGT-A by polar body biopsy and comprehensive genome hybridisation increases cost per live birth and requires high financial spending per miscarriage averted.
引用
- Neumann K, Sermon K, Bossuyt P, et al. An economic analysis of preimplantation genetic testing for aneuploidy by polar body biopsy in advanced maternal age. BJOG. 2020. PMID: 31930663. doi:10.1111/1471-0528.16089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。